Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status approved
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII X6Q56QN5QC
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Back pain15.03.04.005--
Basal cell carcinoma23.08.02.001; 16.03.02.0010.000895%Not Available
Bile duct stone09.02.02.0030.000112%Not Available
Blepharitis23.03.04.012; 06.04.04.001--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood creatinine increased13.13.01.004--
Blood iron decreased13.11.01.006--Not Available
Blood urea increased13.13.01.006--Not Available
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.0040.000112%Not Available
Bowen's disease23.08.02.004; 16.03.02.0040.000672%Not Available
Breast cancer21.05.01.003; 16.10.01.0010.000616%Not Available
Bromosulphthalein test abnormal13.03.04.021--Not Available
Cardiac arrest02.03.04.0010.000392%
Cardiac failure02.05.01.0010.001007%
Cardiomegaly02.04.02.0010.000168%Not Available
Cataract06.06.01.0010.000224%
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000560%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.001119%Not Available
Chills08.01.09.001; 15.05.03.016--
Cholecystitis09.03.01.0010.000112%
Cholelithiasis09.03.01.0020.000280%Not Available
Cholestasis09.01.01.0010.000112%Not Available
Chromaturia20.02.01.0020.000112%
Chronic myeloid leukaemia16.01.07.001; 01.10.07.0010.000783%Not Available
Colon cancer16.13.01.001; 07.21.01.0010.000504%Not Available
Constipation07.02.02.001--
Cough22.02.03.0010.001007%
Cutaneous vasculitis23.06.02.001; 10.02.02.003; 24.12.04.0080.000112%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene